{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T04:41:16Z","timestamp":1759380076656,"version":"build-2065373602"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2025.1680916","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T04:21:38Z","timestamp":1759378898000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Calendar time trends in synchronous metastatic urinary bladder cancer before and after the introduction of immune checkpoint inhibitors: a nation-wide population-based cohort study"],"prefix":"10.3389","volume":"15","author":[{"given":"Karin","family":"S\u00f6derkvist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christel","family":"H\u00e4ggstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oskar","family":"Hagberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Firas","family":"Aljabery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Truls","family":"G\u00e5rdmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Holmberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abolfazl","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Jerlstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Kj\u00f6lhede","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per-Uno","family":"Malmstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Sherif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredrik","family":"Liedberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Ull\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"100266","DOI":"10.1016\/j.ctarc.2020.100266","article-title":"Utilization of systemic treatment for metastatic bladder cancer in everyday practice: Results of a nation-wide population-based cohort study","volume":"25","author":"Richters","year":"2020","journal-title":"Cancer Treat Res Commun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2340\/sju.v58.5923","article-title":"Initial management and survival of patients with primary metastatic bladder cancer before the immunotherapy era: a population-based study from Norway","volume":"58","author":"M\u00f8ller","year":"2023","journal-title":"Scand J Urol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)42494-3","article-title":"M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium","volume":"139","author":"Sternberg","year":"1988","journal-title":"J Urol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.3571","article-title":"Randomized phase II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986","volume":"30","author":"De Santis","year":"2012","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.6979","article-title":"Randomized phase III study comparing paclitaxel\/cisplatin\/gemcitabine and gemcitabine\/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987","volume":"30","author":"Bellmunt","year":"2012","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2340\/1651-226X.2025.43484","article-title":"Treatment patterns in patients with locally advanced and metastatic bladder cancer in Denmark 2015-2023 - an updated analysis","volume":"64","author":"N\u00f8rgaard","year":"2025","journal-title":"Acta Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0298","article-title":"Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis","volume":"20","author":"Kearney","year":"2024","journal-title":"Future Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.8071","article-title":"Second-line chemotherapy for advanced urothelial cancer: because we should or because we can","volume":"27","author":"Dreicer","year":"2009","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.5534","article-title":"Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract","volume":"27","author":"Bellmunt","year":"2009","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35077","article-title":"Contemporary survival in metastatic bladder cancer patients: A population-based study","volume":"155","author":"Di Bello","year":"2024","journal-title":"Int J Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"e064898","DOI":"10.1136\/bmjopen-2022-064898","article-title":"Cohort profile: bladder cancer data base Sweden (BladderBaSe) 2","volume":"12","author":"H\u00e4ggstr\u00f6m","year":"2022","journal-title":"0. BMJ Open"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.10.061","article-title":"Comorbidity, treatment and mortality: a population based cohort study of prostate cancer in PCBaSe Sweden","volume":"185","author":"Berglund","year":"2011","journal-title":"J Urol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"B18","volume-title":"Longitudinal integration database for health insurance and labor market studies","author":"Sweden","year":"2010"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.08.037","article-title":"Gender and bladder cancer: A collaborative review of etiology, biology, and outcomes","volume":"69","author":"Dobruch","year":"2016","journal-title":"Eur Urol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/JU.0000000000000350","article-title":"A nationwide, population based analysis of patients with organ confined, muscle invasive bladder cancer not receiving curative intent therapy in Sweden from 1997 to 2014","volume":"202","author":"Westergren","year":"2019","journal-title":"J Urol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2019.01.020","article-title":"The impact of squamous histology on survival in patients with muscle-invasive bladder cancer","volume":"37","author":"Matulay","year":"2019","journal-title":"Urol Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.07.032","article-title":"Effectiveness of first-line immune checkpoint blockade versus carboplatin-based chemotherapy for metastatic urothelial cancer","volume":"76","author":"Feld","year":"2019","journal-title":"Eur Urol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01213","article-title":"Long-term outcomes in KEYNOTE-052: phase II study investigating first-line pembrolizumab in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer","volume":"38","author":"Vuky","year":"2020","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1680916\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T04:21:40Z","timestamp":1759378900000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1680916\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":24,"alternative-id":["10.3389\/fonc.2025.1680916"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1680916","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"article-number":"1680916"}}